Chow FCL, Chok KSH. Colorectal liver metastases: An update on multidisciplinary approach. World J Hepatol 2019; 11(2): 150-172 [PMID: 30820266 DOI: 10.4254/wjh.v11.i2.150]
Corresponding Author of This Article
Kenneth Siu-Ho Chok, FRCS(Ed), Associate Professor, Department of Surgery and State Key Laboratory for Liver Research, the University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China. chok6275@hku.hk
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Feb 27, 2019; 11(2): 150-172 Published online Feb 27, 2019. doi: 10.4254/wjh.v11.i2.150
Colorectal liver metastases: An update on multidisciplinary approach
Felix Che-Lok Chow, Kenneth Siu-Ho Chok
Felix Che-Lok Chow, Department of Surgery, Queen Mary Hospital, Hong Kong, China
Kenneth Siu-Ho Chok, Department of Surgery and State Key Laboratory for Liver Research, the University of Hong Kong, Hong Kong, China
Author contributions: Chok KSH conceptualized and supervised the study; Chow FCL did the literature review and wrote the manuscript; both authors approved the submitted version of manuscript.
Conflict-of-interest statement: None of the authors has any conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Kenneth Siu-Ho Chok, FRCS(Ed), Associate Professor, Department of Surgery and State Key Laboratory for Liver Research, the University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China. chok6275@hku.hk
Telephone: +852-22553025 Fax: +852-28165284
Received: October 5, 2018 Peer-review started: October 6, 2018 First decision: November 15, 2018 Revised: November 24, 2018 Accepted: December 4, 2018 Article in press: December 5, 2018 Published online: February 27, 2019 Processing time: 145 Days and 4.5 Hours
Core Tip
Core tip: Surgery offers the only hope of cure in colorectal liver metastasis. It can be performed if complete metastasectomy is attainable. There is no consensus on the ideal management strategy for synchronous disease. A subset of patients presenting with unresectable disease may become eligible for resection after liver remnant augmentation or conversion therapy (chemo-therapeutics +/- biological agents). Amid increasing application of loco-regional therapies to colorectal liver metastasis, their role in the treatment paradigm remains to be defined. Refined patient selection – with greater emphasis on tumour biology – is essential to improving treatment outcome. The multidisciplinary approach helps determine the optimal treatment strategy from an expanding armamentarium of therapeutic options for each patient.
